AAVivo
AAVivo lists CD19 AVO-100, BCMA AVO-101, and dual BCMA/CD19 AVO-102 using T-cell-targeted AAV. The disclosed activities include vector production and construct optimization, not verified clinical dosing. AVO-103 is a TCR program and is kept separate from CAR-T.
Corporate information
- Company entity
- AAVivo
- Headquarters / principal office
- 8300 Cypress Creek Parkway, Suite 100, Houston, Texas, United States ↗
- Founded
- 2025 (Delaware incorporation) ↗
- Ownership / capital status
- PrivateFunded by Virovek Inc.; independent external round not verified ↗
- Official corporate reference
- https://aavivo.com/our-programs/ ↗
- LinkedIn company page
- Independent company page not verified
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
AAVivo lists CD19 AVO-100, BCMA AVO-101, and dual BCMA/CD19 AVO-102 using T-cell-targeted AAV. The disclosed activities include vector production and construct optimization, not verified clinical dosing. AVO-103 is a TCR program and is kept separate from CAR-T.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.
Original sources
- AAVivo — primary program / ownership disclosure
- AAVivo — company, leadership and headquarters
- Founding / incorporation disclosure — scope stated in field